Maternal Fetal Medicine: Collaborative Partnerships in TMA Care
We were pleased to recently welcome Dr Richard Burwick (California, USA) to our global network of aHUS clinicians and investigators. Some…
aHUS clinical trials are not that easy
To answer some of the questions in the aHUS Patients Research Agenda clinical trials will be needed. Take the issue of…
Improving outcomes for “aHUS” patients, I was there.
As an aHUS advocate you can often be surprised by events. Nearly three months ago I received an e mail inviting…
aHUS Patient Meeting Aug 2022 – USTMA
Atypical HUS patients, family caregivers, and aHUS advocates are invited to attend a full day virtual meeting which will be held…
TMAs and aHUS illustrated
Here is a most unusual clinical article from earlier this year. In Thrombotic microangiopathies : An Illustrated review the Abou-Ismail Group…
Difference in aHUSs
This question about difference in disease triggers and treatments from Jeff did not feature in the RDD2022 video but was given…
aHUS care pathway
The care pathway for aHUS patients has been looked at in detail in Global Action’s Diagnosis Process Study ( for reports…
aHUS limitations
Zinovieva asked two related questions in the RDD 2020 video The issues of what provokes ( or triggers) the development of…
aHUS remission chance and relapse risk
Remission from aHUS is different from having been cured because there is still an uncertainty that aHUS can return. If that…
- Go to the previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- Go to the next page